(Q36626251)

15 August 2017

1 reference

title

The relationship between patient satisfaction and treatment outcomes in schizophrenia (English)

1 reference

15 August 2017

0 references

1 reference

Pierre Chue

1

1 reference

PubMed ID

17046986

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Journal of Psychopharmacology

15 August 2017

1 reference

15 August 2017

20

1 reference

15 August 2017

6 Suppl

1 reference

15 August 2017

38-56

1 reference

Long-term depot antipsychotics. A risk-benefit assessment

15 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. 1993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

The quest for well-being: a qualitative study of the experience of taking antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Detecting improvement in quality of life and symptomatology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Research on the influence that communication in psychiatric encounters has on treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Adverse effects of atypical antipsychotic agents and their effects on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Measuring client satisfaction with assertive community treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Patient satisfaction with outpatient psychiatric treatment: the role of diagnosis, pharmacotherapy, and perceived therapeutic change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Patients' subjective experiences of antipsychotics: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Quality of life in schizophrenia: contributions of anxiety and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Does risperidone have a place in the treatment of nonschizophrenic patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Integrated care in schizophrenia: a 2‐year randomized controlled study of two community‐based treatment programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

How antipsychotics work: the patients' perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Long-acting risperidone in stable patients with schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

The development and internal consistency of the satisfaction with Antipsychotic Medication Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Tolerability of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

The personal impact of schizophrenia in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Systematic review of patient and nurse attitudes to depot antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Subjective experiences of clozapine treatment by patients with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

Guidelines for depot antipsychotic treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071246

21 January 2018

Identifiers

DOI

10.1177/1359786806071246

1 reference

15 August 2017

1 reference

PubMed ID

17046986